Manufacturing

The complexity of molecular transformations in pharmaceutical synthesis demands enzymes that maintain high selectivity without sacrificing the speed of the chemical reaction. These biological catalysts are the foundation of many life-sustaining processes, yet their natural forms are rarely suited

The global medical supply chain relies heavily on Indian manufacturing, making any shift in domestic pharmaceutical regulations a matter of international concern for healthcare providers and patients alike. The Ministry of Health recently proposed rigorous amendments to the Drugs Rules, signaling a

The Carlsbad facility brings end-to-end viral vector solutions and aseptic fill-finish capabilities to Lonza, catering specifically to the burgeoning cell and gene therapy market. This strategic acquisition of five specialized contract development and manufacturing organization (CDMO) sites from

Institutional investors now manage portfolios by treating inadequate environmental, social, and governance strategies as material financial liabilities rather than mere corporate social responsibility gestures. This seismic shift marks the end of an era where pharmaceutical companies could rely on

Siloed data across quality, manufacturing, and post-market surveillance prevents manufacturers from seeing the cross-functional impacts that regulatory AI tools now identify instantly. The medical device industry is currently navigating a period of unprecedented transformation, where the

A dual-sourcing strategy ensures that the pursuit of environmental milestones does not compromise the security of the supply chain for essential medical treatments. As global healthcare systems face unprecedented demand, the pharmaceutical industry is increasingly pressured to harmonize life-saving